Posted by Michael Wonder on 11 Feb 2022
Lilly's bebtelovimab receives emergency use authorisation for the treatment of mild to moderate COVID-19
11 February 2022 - Bebtelovimab neutralises Omicron as demonstrated by pseudovirus and authentic virus data
The U.S. FDA has issued an emergency use authorisation for bebtelovimab, an antibody that demonstrates neutralisation against the Omicron variant, Eli Lilly announced today.
